Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BASI OTCMKTS:BIOQ NASDAQ:CBLI OTCMKTS:HPPI NASDAQ:TENX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBASIBioanalytical Systems$0.25+0.4%$18.71$3.05▼$21.08$2.82M1.92122,925 shs572,125 shsBIOQBioqual$32.50$35.43$32.50▼$43.55$28.93M-0.21198 shsN/ACBLICleveland BioLabs$3.19$1.62▼$10.97$6K0.7271,922 shs3,245 shsHPPIHedgePath Pharmaceuticals$0.08$0.08$0.04▼$0.32$31.44M-1.1619,283 shsN/ATENXTenax Therapeutics$11.91+5.1%$12.60$5.34▼$18.38$316.49M0.98488,848 shs572,279 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBASIBioanalytical Systems0.00%0.00%0.00%-33.91%-88.58%BIOQBioqual0.00%0.00%-7.67%-13.36%-26.55%CBLICleveland BioLabs0.00%0.00%0.00%0.00%+33.33%HPPIHedgePath Pharmaceuticals0.00%+10.21%+2.24%-3.57%+74.80%TENXTenax Therapeutics-1.90%+5.59%-5.43%-27.19%+85.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBASIBioanalytical Systems$0.25+0.4%$18.71$3.05▼$21.08$2.82M1.92122,925 shs572,125 shsBIOQBioqual$32.50$35.43$32.50▼$43.55$28.93M-0.21198 shsN/ACBLICleveland BioLabs$3.19$1.62▼$10.97$6K0.7271,922 shs3,245 shsHPPIHedgePath Pharmaceuticals$0.08$0.08$0.04▼$0.32$31.44M-1.1619,283 shsN/ATENXTenax Therapeutics$11.91+5.1%$12.60$5.34▼$18.38$316.49M0.98488,848 shs572,279 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBASIBioanalytical Systems0.00%0.00%0.00%-33.91%-88.58%BIOQBioqual0.00%0.00%-7.67%-13.36%-26.55%CBLICleveland BioLabs0.00%0.00%0.00%0.00%+33.33%HPPIHedgePath Pharmaceuticals0.00%+10.21%+2.24%-3.57%+74.80%TENXTenax Therapeutics-1.90%+5.59%-5.43%-27.19%+85.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBASIBioanalytical Systems 0.00N/AN/AN/ABIOQBioqual 0.00N/AN/AN/ACBLICleveland BioLabs 0.00N/AN/AN/AHPPIHedgePath Pharmaceuticals 0.00N/AN/AN/ATENXTenax Therapeutics 2.83Moderate Buy$39.67241.48% UpsideCurrent Analyst Ratings BreakdownLatest BIOQ, BASI, CBLI, HPPI, and TENX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026TENXTenax Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$20.00 ➝ $50.006/1/2026TENXTenax Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight3/17/2026TENXTenax Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$35.00(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBASIBioanalytical Systems$60.47M0.05$0.00 per share558.40$0.69 per share0.37BIOQBioqual$48.87M0.59$1.48 per share21.99$40.42 per share0.80CBLICleveland BioLabs$260K0.00N/AN/A$0.87 per share0.00HPPIHedgePath PharmaceuticalsN/AN/AN/AN/A($0.01) per shareN/ATENXTenax TherapeuticsN/AN/AN/AN/A$10.42 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBASIBioanalytical Systems-$4.68M-$0.35N/A6.34N/A-7.75%-42.74%-6.38%N/ABIOQBioqual-$1.05M-$1.08N/AN/AN/A-2.27%-2.69%-1.50%N/ACBLICleveland BioLabs-$2.40MN/AN/AN/AN/AN/A-32.84%-31.29%N/AHPPIHedgePath Pharmaceuticals-$4.55MN/AN/AN/AN/AN/AN/A-246.03%N/ATENXTenax Therapeutics-$52.60M-$1.40N/AN/AN/AN/A-56.32%-53.12%8/12/2026 (Estimated)Latest BIOQ, BASI, CBLI, HPPI, and TENX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026TENXTenax Therapeutics-$0.40-$0.35+$0.05-$0.35N/AN/A4/21/2026Q3 2026BIOQBioqualN/A-$0.84N/A-$0.84N/A$9.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBASIBioanalytical SystemsN/AN/AN/AN/AN/ABIOQBioqualN/AN/AN/AN/AN/ACBLICleveland BioLabsN/AN/AN/AN/AN/AHPPIHedgePath PharmaceuticalsN/AN/AN/AN/AN/ATENXTenax TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBASIBioanalytical Systems2.490.480.46BIOQBioqualN/A4.014.01CBLICleveland BioLabsN/A45.9345.93HPPIHedgePath PharmaceuticalsN/A6.766.76TENXTenax TherapeuticsN/A14.5214.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBASIBioanalytical Systems10.62%BIOQBioqualN/ACBLICleveland BioLabs5.09%HPPIHedgePath PharmaceuticalsN/ATENXTenax Therapeutics1.67%Insider OwnershipCompanyInsider OwnershipBASIBioanalytical Systems11.46%BIOQBioqual39.24%CBLICleveland BioLabs1.03%HPPIHedgePath Pharmaceuticals4.80%TENXTenax Therapeutics3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBASIBioanalytical Systems39711.13 millionN/ANot OptionableBIOQBioqual114890,000543,000Not OptionableCBLICleveland BioLabs415.48 millionN/ANot OptionableHPPIHedgePath Pharmaceuticals1370.45 millionN/ANot OptionableTENXTenax Therapeutics926.52 million25.54 millionNot OptionableBASI, BIOQ, HPPI, CBLI, and TENX HeadlinesRecent News About These CompaniesTenax Therapeutics Announces Results of 2026 Annual MeetingJune 4, 2026 | tipranks.comTenax Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:TENXMay 24, 2026 | benzinga.comTenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 12, 2026 | globenewswire.comTenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8, 2026 | globenewswire.comTenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial OfficerMay 4, 2026 | globenewswire.comTenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial OfficerApril 22, 2026 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Tenax Therapeutics (TENX)April 15, 2026 | theglobeandmail.comTenax Therapeutics (TENX) price target increased by 13.86% to 29.32March 27, 2026 | msn.comTenax Therapeutics: A Binary Bet With Heavy Downside LikelyMarch 18, 2026 | seekingalpha.comCantor Fitzgerald initiates coverage of Tenax Therapeutics (TENX) with overweight recommendationMarch 18, 2026 | msn.comTenax wins bullish view at Cantor ahead of pivotal readoutMarch 17, 2026 | seekingalpha.comTenax Therapeutics, Inc.: Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 10, 2026 | finanznachrichten.deTenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 10, 2026 | globenewswire.comTenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare ConferenceMarch 3, 2026 | globenewswire.comTenax Therapeutics: Some Future PotentialFebruary 26, 2026 | seekingalpha.comTenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026February 4, 2026 | globenewswire.comTenax Therapeutics: A Speculative BuyJanuary 9, 2026 | seekingalpha.comGuggenheim Doubles Tenax (TENX) PT, Names Stock Top PickJanuary 8, 2026 | insidermonkey.comWhy Tenax Therapeutics, Inc.’s (TENX) Stock Is Up 17.17%January 5, 2026 | aaii.comATenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric RepricingJanuary 5, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026Oil Could Dip, But These 3 Energy Stocks Still Look Built to WinBy Chris Markoch | June 15, 2026Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround PlanBy Thomas Hughes | June 17, 2026BASI, BIOQ, HPPI, CBLI, and TENX Company DescriptionsBioanalytical Systems NASDAQ:BASIBioanalytical Systems, Inc., doing business as Inotiv, provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. BioVaxys has an agreement with Inotiv to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.Bioqual OTCMKTS:BIOQ$32.50 0.00 (0.00%) As of 06/12/2026Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.Cleveland BioLabs NASDAQ:CBLICytocom, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.HedgePath Pharmaceuticals OTCMKTS:HPPI$0.08 0.00 (0.00%) As of 06/16/2026HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida. HedgePath Pharmaceuticals, Inc. is a subsidiary of Mayne Pharma Ventures Pty Ltd.Tenax Therapeutics NASDAQ:TENX$11.88 +0.55 (+4.86%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Fox Captures The Living Room With $22B Roku Buy Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan Microsoft’s Xbox Problem Is Bigger Than a Console War Could a Tesla-SpaceX Merger Be Closer Than Investors Think? Flying Under the Radar: Lockheed Martin's $2.8B Stealth Setup Bread’s Comeback Is Real—But Is the Easy Money Gone? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
